Loading stock data…
Mesa Laboratories (MLAB)
$99.53-2.89 (-2.82%)
After Hours$99.53+0.00 (+0.00%)· Last close Jun 29
Mesa Laboratories, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Mesa Laboratories, Inc. in the Technology sector is trading at $99.53 with a market capitalization of $558M. Wall Street consensus targets $112.00 (2 analysts), implying a +12.5% move over the next 12 months. The stock is currently 13% below its 52-week high of $113.99, remaining 16.1% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +12.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $65.13M↑ | $60.74M↑ | $59.54M↓ | $62.13M |
| Gross Profit | — | $41.80M↑ | $37.33M↑ | $36.94M↓ | $38.41M |
| Operating Income | — | $7.97M↑ | $4.72M↑ | $3.06M↑ | $1.47M |
| Net Income | — | $3.63M↑ | $2.48M↓ | $4.74M↑ | -$7.11M |
Peer Comparison
AAPLMSFTGOOGL
Fundamentals
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control seg...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$558.38M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.48%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.81%
Volume
Today's trading volume
144,407
Recent News
Mesa Laboratories: Priced for the Problem, Not the Platform
Mesa Laboratories is priced against a declining genomics drag, while its compliance consumable segment embedded in pharma sterilization mandates earns margins the blended multiple obscures.
3 Stocks Estimated To Be Trading 16.4% To 42% Below Intrinsic Value
In the last week, the United States market has stayed flat, yet it is up 26% over the past year with earnings forecast to grow by 17% annually. In such a robust market environment, identifying stocks trading below their intrinsic value can present unique opportunities for investors seeking potential growth.
Why Mesa Laboratories Stock Is Getting Hit With a Huge Sell-Off Today
Investors aren't happy with Mesa Labs latest quarterly report.
Undervalued Small Caps With Insider Buying Across Regions
The United States market has experienced a flat week, yet it has shown a robust 27% increase over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this context of growth and stability, identifying stocks that are currently undervalued can offer potential opportunities for investors seeking to capitalize on insider confidence and regional strengths.
Undervalued Small Caps With Insider Buying Across Regions To Consider
Over the last 7 days, the United States market has risen by 4.0%, contributing to a remarkable 39% increase over the past year, with earnings projected to grow by 16% annually in the coming years. In this dynamic environment, identifying good stocks often involves looking for companies that are not only undervalued but also show signs of insider confidence, such as recent buying activity.